电子临床决策支持工具用于住院抗菌药物管理的随机对照试验
本研究在4家医院开展交叉随机对照试验,评估WISCA工具对成人住院患者经验性抗菌药物处方的影响,共纳入6849例。结果显示WISCA对尿路感染和腹腔胆道感染结局无改善,但基于指南的干预与蜂窝织炎住院时间缩短和社区获得性肺炎30天死亡率降低相关。
要点
- WISCA工具对尿路感染和腹腔胆道感染结局无改善。
核心结论
- 使用WISCA工具与尿路感染和腹腔胆道感染结局改善无关。
- 基于指南的干预与蜂窝织炎住院时间缩短和社区获得性肺炎死亡率降低相关。
研究设计与样本
- 在4家医院进行的交叉随机对照试验。
- 纳入接受经验性抗菌药物治疗尿路感染、腹腔胆道感染、肺炎或非脓性蜂窝织炎的成人住院患者,共6849例。
主要发现
- 干预组与对照组总体结局无差异。
关键数值与推荐
- 主要结局为住院时间;次要结局包括30天死亡率、30天再入院、艰难梭菌感染、多重耐药革兰阴性菌获得和抗生素费用。
临床怎么用
- 对于蜂窝织炎和社区获得性肺炎,基于指南的抗菌药物管理干预可能缩短住院时间或降低死亡率。
- WISCA工具在尿路感染和腹腔胆道感染中未显示额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The weighted incidence syndromic combination antibiogram (WISCA) is an antimicrobial stewardship tool that utilizes electronic medical record data to provide real-time clinical decision support regarding empiric antibiotic prescription in the hospital setting. The aim of this study was to determine the impact of WISCA utilization for empiric antibiotic prescription on hospital length of stay (LOS). METHODS: We performed a crossover randomized controlled trial of the WISCA tool at 4 hospitals. Study participants included adult inpatients receiving empiric antibiotics for urinary tract infection (UTI), abdominal-biliary infection (ABI), pneumonia, or nonpurulent cellulitis. Antimicrobial stewardship (ASP) physicians utilized WISCA and clinical guidelines to provide empiric antibiotic recommendations. The primary outcome was LOS. Secondary outcomes included 30-day mortality, 30-day readmission, Clostridioides difficile infection, acquisition of multidrug-resistant gram-negative organism (MDRO), and antibiotics costs. RESULTS: In total, 6849 participants enrolled in the study. There were no overall differences in outcomes among the intervention versus control groups. Participants with cellulitis in the intervention group had significantly shorter mean LOS compared to participants with cellulitis in the control group (coefficient estimate = 0.53 [-0.97, -0.09], P = .0186). For patients with community acquired pneumonia (CAP), the intervention group had significantly lower odds of 30-day mortality compared to the control group (adjusted odds ratio [aOR] .58, 95% confidence interval [CI], .396, .854, P = .02). CONCLUSIONS: Use of WISCA was not associated with improved outcomes for UTI and ABI. Guidelines-based interventions were associated with decreased LOS for cellulitis and decreased mortality for CAP.
引用
- Ridgway JP, Robicsek A, Shah N, et al. A Randomized Controlled Trial of an Electronic Clinical Decision Support Tool for Inpatient Antimicrobial Stewardship. Clin Infect Dis. 2021. PMID: 32712674. doi:10.1093/cid/ciaa1048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。